Clinical Trials /

Epigenetic Reprogramming in Relapse/Refractory AML

NCT03263936

Description:

This is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).

Related Conditions:
  • Acute Myeloid Leukemia
Recruiting Status:

Recruiting

Phase:

Phase 1

Trial Eligibility

Document

Title

  • Brief Title: Epigenetic Reprogramming in Relapse/Refractory AML
  • Official Title: Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML

Clinical Trial IDs

  • ORG STUDY ID: T2016-003
  • NCT ID: NCT03263936

Conditions

  • Acute Myelogenous Leukemia

Interventions

DrugSynonymsArms
DecitabineDacogenOther
VorinostatZolinza, SAHA, suberoylanilide acidOther
Filgrastim (G-CSF)G-CSF, neupogenOther
FludarabineFludaraOther
CytarabineCytosine arabinoside, Ara-C, CytosarOther

Purpose

This is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).

Detailed Description

      Decitabine is a demethylating agent and vorinostat is a HDAC inhibitor. The use of
      demethylating agents and HDAC inhibitors in combination have been previously shown to have
      synergistic effects in altering neoplastic pathways of cancer cells and be well tolerated in
      human clinical studies. With the ability of decitabine and vorinostat to alter the abnormal
      cellular pathways of leukemic blasts and essentially turn off anti-apoptotic proteins, the
      leukemia cells have become primed for cytotoxic cell kill via chemotherapeutic agents. This
      study will ask the question as to whether or not the combination of decitabine and vorinostat
      followed by chemotherapy is feasible and whether it can positively impact outcome in patients
      with relapsed or refractory acute myelogenous leukemia.
    

Trial Arms

NameTypeDescriptionInterventions
OtherOtherdecitabine, vorinostat, fludarabine, high dose cytarabine, filgrastim (G-CSF)
  • Decitabine
  • Vorinostat
  • Filgrastim (G-CSF)
  • Fludarabine
  • Cytarabine

Eligibility Criteria

        Inclusion Criteria:

        - Patients must be ≥ 1 and ≤25 years of age.

        Diagnosis:

        - Patients with AML must have ≥ 5% blasts (by morphology) in the bone marrow

          -  Patients may have CNS or other sites of extramedullary disease. No cranial irradiation
             is allowed during the protocol therapy.

          -  Patients with secondary AML are eligible

          -  Patients with Down syndrome and DNA fragility syndromes (such as Fanconi anemia, Bloom
             syndrome) are excluded.

        Performance Level:

        - Karnofsky >50% for patients >16 years of age and Lansky > 50% for patients ≤ 16 years of
        age (See Appendix II for Performance Scales)

        Prior therapy

        - Patients must have fully recovered from the acute toxic effects of all prior
        chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

          1. Phase 1

             - Any patient with AML in 1st or greater relapse, OR

             - Patients with AML failed to go into remission after first or greater relapse, OR

             - Patients with AML failed to go into remission from original diagnosis after two or
             more induction attempts.

          2. Cytoreduction with hydroxyurea - Hydroxyurea can be initiated and continued for up to
             24 hours prior to the start of decitabine/vorinostat. It is recommended to use
             hydroxyurea in patients with significant leukocytosis (WBC >50,000/L) to control blast
             count before initiation of systemic protocol therapy.

          3. Patients who relapsed while they are receiving cytotoxic therapy

             - At least 14 days must have elapsed since the completion of the cytotoxic
             therapy,except Intrathecal chemotherapy.

             Hematopoietic stem cell transplant (HSCT):

             - Patients who have experienced their relapse after a HSCT are eligible, provided they
             have no evidence of acute or chronic Graft-versus-Host Disease (GVHD).

             Hematopoietic growth factors:

             - It must have been at least 7 days since the completion of therapy with GCSF or other
             growth factors at the time of enrollment. It must have been at least 14 days since the
             completion of therapy with pegfilgrastim (Neulasta ®)

             Biologic (anti-neoplastic agent):

             -At least 7 days after the last dose of a biologic agent. For agents that have known
             adverse events occurring beyond 7 days after administration, this period must be
             extended beyond the time during which adverse events are known to occur. The duration
             of this interval must be discussed with the study chair.

             Monoclonal antibodies: At least 3 half-lives of the antibody must have elapsed after
             the last dose of monoclonal antibody (i.e. Gemtuzumab = 36 days)

             Immunotherapy: At least 42 days after the completion of any time of immunotherapy,
             e.g. tumor vaccines or CAR T-cell therapy.

             XRT: Cranio or craniospinal XRT is prohibited during protocol therapy. No washout
             period is necessary for radiation given to non-CNS chloromas; >90 days must have
             elapsed if prior TBI, cranio or craniospinal XRT.

             Prior Demethylating and/or HDAC Inhibitor Therapy: Patients who have received prior
             DNMTi (e.g. decitabine) and/or HDACi (e.g. vorinostat) therapy are eligible to
             participate in this Phase 1 study. At least 7 days must have passed from prior DNMTi
             or HDACi as a washout period.

             Renal and hepatic function: Patients must have adequate renal and hepatic functions as
             indicated by the following laboratory values:

             A. Adequate renal function defined as: Patient must have a calculated creatinine
             clearance or radioisotope GFR ≥ 70ml/min/1.73m2 OR a normal serum creatinine based on
             age/gender.

             B. Adequate Liver Function Defined as: Direct bilirubin < 1.5 x upper limit of normal
             (ULN) for age or normal, AND alanine transaminase (ALT) < 5 x ULN for age. The hepatic
             requirements are waived for patients with known or suspected liver involvement by
             leukemia. This must be reviewed by and approved by the study chair or vice chair.

             Adequate Cardiac Function Defined as: Shortening fraction of ≥ 27% by echocardiogram,
             OR ejection fraction of ≥ 50% by radionuclide angiogram (MUGA).

             Reproductive Function A. Female patients of childbearing potential must have a
             negative urine or serum pregnancy test confirmed within 2 weeks prior to enrollment.

             B. Female patients with infants must agree not to breastfeed their infants while on
             this study.

             C. Male and female patients of child-bearing potential must agree to use an effective
             method of contraception approved by the investigator during the study and for a
             minimum of 6 months after study treatment.

             Exclusion Criteria:

             -No NG or G-Tube administration of Vorinostat is allowed. Capsule must be swallowed
             whole or given as oral suspension.

             -They are currently receiving other investigational drugs.

             -There is a plan to administer non-protocol chemotherapy, radiation therapy, or
             immunotherapy during the study period.

             -They have significant concurrent disease, illness, psychiatric disorder or social
             issue that would compromise patient safety or compliance, interfere with consent,
             study participation, follow up, or interpretation of study results.

             -They have a known allergy to any of the drugs used in the study.

             -Patients with Down syndrome are excluded.

               -  Patients with DNA fragility syndromes are excluded (e.g. Fanconi Anemia, Bloom
                  Syndrome)

               -  They are receiving valproic acid (VPA) therapy.

               -  Patients with Acute Promyelocytic Leukemia (APL, APML) are excluded

               -  Patients with documented active and uncontrolled infection at the time of study
                  entry are not eligible
      
Maximum Eligible Age:25 Years
Minimum Eligible Age:1 Year
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:The dose of decitabine that can be safely given with vorinostat, fludarabine, high dose cytarabine and G-CSF (FLAG)
Time Frame:during course 1, approx 5 weeks
Safety Issue:
Description:The incidence of dose limiting toxicity (DLT) will be measured. The maximum tolerated dose will be the highest study dose at which 1 or fewer of six patients experience DLT during cycle 1 of therapy

Secondary Outcome Measures

Measure:To examine peripheral blood mononuclear cells for immunophenotypic changes.
Time Frame:approx 8 weeks
Safety Issue:
Description:To examine peripheral blood mononuclear cells for immunophenotypic changes using peripheral blood samples
Measure:To analyze plasma for cytokine content.
Time Frame:approx 8 weeks
Safety Issue:
Description:To analyze plasma for cytokine content using plasma samples.
Measure:To analyze the correlation between biological changes and clinical response.
Time Frame:approx 8 weeks
Safety Issue:
Description:To analyze the correlation between biological changes and clinical response using standard statistical methods
Measure:To establish the extent of hypomethylation of peripheral blood (PB) and bone marrow (BM) pre- and post- decitabine and vorinostat treatment:
Time Frame:approx 8 weeks
Safety Issue:
Description:Reduced representation bisulfite sequencing (RRBS) will be used to analyze the genome-wide methylation profiles on a single nucleotide level; To quantitatively assess global changes in DNA methylation, a LINE-methylation assay will be utilized and specific genes monitored through advanced Infinium MethylationEPIC BeadChip from Illumina. Chromatin immunoprecipitation (ChIP) with antibodies specific for histone modifications associated with transcriptional activation (H3K4me3 and H3K27ac) and repression (H3K9me3 and H3K27me3) and isotype controls, followed by DNA sequencing (ChIP-seq); RNA sequencing analysis will be used to measure global transcriptome changes. Profiles of CD33+ umbilical cord blood cells, whole bone marrow, or Peripheral Blood Stem Cells (PBSCs) will be used as normal controls for each sample.
Measure:To analyze the correlation between DNA methylation and gene expression pre- and post-treatment with decitabine and vorinostat.
Time Frame:approx 8 weeks
Safety Issue:
Description:Assessment of the in vivo effects of combined DNMTi/HDACi on the functional epigenetic profile by comparing the following in paired pre- (Day 0) and post-exposure (Day 5, Day 14 and Day 35) leukemic blasts: Reversal of DNA promoter hypermethylation of "repressed" genes of interest using RRBS, validated with Pyrosequencing-based methylation assay; Increase in H3K9/14 acetylation in association with "repressed" genes of interest using H3K9/14 ChIP-seq, validated with ChIP-qPCR; Reversal of transcriptional silencing of "repressed" genes of interest using RNA seq, validated by qRT-PCR. Since significant acute cell kill is unlikely during the 5-day "window" of DNMTi/HDACi, we will have a unique opportunity to assess the in vivo effects of epigenetic therapy with the Day 5 sample. The Day 14 peripheral blood and Day 35 marrow samples will also contribute in patients whose leukemic blasts persist at these time points.

Details

Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Therapeutic Advances in Childhood Leukemia Consortium

Trial Keywords

  • Relapse
  • Myelogenous
  • Leukemia
  • Refractory
  • Acute
  • Pediatric

Last Updated